Clinical and radiological outcomes of ustekinumab in pediatric perianal Crohn's disease: a multicenter retrospective study from the Pediatric IBD Porto Group of ESPGHAN

Orlin, Ido, Younis, Balsam, Gasparetto, Marco, Yerushalmy-Feler, Anat, Norsa, Lorenzo, Sokollik, Christiane, Rohani, Pejman, Zárubová, Kristýna, D'Arcangelo, Giulia, Pochesci, Saverio, Lozano-Ruf, Ana, Kolho, Kaija-Leena, Griffiths, Anne and Rinawi, Frias (2026) Clinical and radiological outcomes of ustekinumab in pediatric perianal Crohn's disease: a multicenter retrospective study from the Pediatric IBD Porto Group of ESPGHAN. Inflammatory Bowel Diseases. ISSN 1078-0998

Full text not available from this repository. (Request a copy)

Abstract

Background: Perianal Crohn's disease (pCD) is a severe pediatric phenotype with high morbidity. Although antitumor necrosis factor (TNF) agents are first-line therapy, remission is not achieved in a subset of patients. We aimed to evaluate clinical and radiological outcomes of ustekinumab (UST) in pediatric patients with pCD. Methods: This is a multicenter retrospective study including pediatric patients with pCD treated with UST between 2016 and 2023. Primary outcomes were clinical and radiological remission at predefined time points. Clinical remission was defined as absence of fistula drainage without antibiotics or unplanned perianal interventions. Radiological remission was defined as a Pediatric MRI-Based perianal Crohn's Disease (PEMPAC) score of <10 on pelvic MRI. Results: Fifty patients were included, of whom 2 were anti-TNF-naive. The median age at UST initiation was 15 years (IQR 12.4-16.2). Clinical remission was observed in 46% (23/50; P = .006 vs baseline), 48% (23/48; P = .036 vs baseline), and 42% (19/45; P = .13 vs baseline) at weeks 26, 52, and 104, respectively. Radiological remission was 29% (10/34) and 30% (13/43) at weeks 52 and 104, respectively (both P < .01 vs baseline). In multivariable analysis, higher baseline PEMPAC scores were independently associated with lower odds of both clinical (P < .01; OR 0.88, 95% CI 0.68-0.95) and radiological remission (P < .01; OR 0.81, 95% CI 0.62-0.94). Conclusions: UST was associated with perianal clinical remission in a substantial proportion of pediatric patients, approaching 50% at 1 year, and radiological healing in about one-third at 2 years, supporting its potential role in pediatric pCD.

Item Type:	Article
Uncontrolled Keywords:	mri-based pempac index,clinical remission,perianal crohn’s disease,radiological remission,ustekinumab
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User:	LivePure Connector
Date Deposited:	11 Jun 2026 11:07
Last Modified:	14 Jun 2026 05:28
URI:	https://ueaeprints.uea.ac.uk/id/eprint/103360
DOI:	10.1093/ibd/izag091

Actions (login required)

View Item